Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Enhertu Filed in Japan as Adjuvant Therapy for Early Breast Cancer
Daiichi Sankyo said on February 27 that it has filed its antibody drug conjugate Enhertu (trastuzumab deruxtecan) for a label expansion to include its use as an adjuvant therapy for HER2-positive early breast cancer.The company is seeking the nod for…
To read the full story
Related Article
- Enhertu Accepted for EU Review in Post-Neoadjuvant HER2 Breast Cancer
February 20, 2026
BUSINESS
- Ono, AstraZeneca to End Japan Co-Promotion of Forxiga
March 2, 2026
- Enhertu Filed in Japan as Adjuvant Therapy for Early Breast Cancer
March 2, 2026
- Shionogi, Torii File Lotion Form of Corectim in Japan
March 2, 2026
- Arcalis Completes mRNA Drug Facility, Establishes End-to-End CDMO Platform
March 2, 2026
- GSK Files Hep B Drug in Japan as First Global Submission
February 27, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…